Clinical Trial

Salvage Treatment With Glofitamab in R/R B-NHL: a GIMEMA-FIL Study

Completed
View on ClinicalTrials.gov →
Summary
The goal of this observational study is to evaluate the anti-lymphoma activity of glofitamab, administered according to the Compassionate Use Program, in relapsed/refractory B-NHL patients. The main question it aims to answer is the rate of patients in complete response.
Protocol Amendment History 3 changes
critical Trial completed 2026-07-21
notable Enrollment reduced: 96 -> 59 participants 2026-07-21
minor Completion moved earlier: 2026-09 -> 2026-07-15 2026-07-21
Trial Details
NCT Number NCT05927558
Lead Sponsor Gruppo Italiano Malattie EMatologiche dell'Adulto
Conditions B-cell Non Hodgkin Lymphoma, Relapse, Refractory Lymphoma
Enrollment 59 participants
Start Date 2023-12-22
Primary Completion 2026-06-24 (estimated)
Study Completion 2026-06-24 (estimated)
Updated on ClinicalTrials.gov 2026-07-28